



Application No. 10/786,240
 Amendment "A" and Response dated May 4, 2006
 Reply to Office Action mailed February 7, 2006

AMENDMENTS TO THE CLAIMS

This listing of claims replaces all prior versions, and listings, of claims in the application:

Listing of Claims:

1. (Currently Amended) A compound comprising:




wherein:


W is hydrogen;

~~X is selected from the group consisting of CH₂SH, CH₂OH, NHOH, PO₃H₂, pyrazoles, imidazoles, oxazoles, isoxazoles, thiazoles, isothiazoles, triazoles, oxadiazoles and thiadiazoles; and~~

Y is selected from the group consisting of: ~~COCZ, C(=W)CZ, SOCZ, SO₂CZ,~~



Application No. 10/786,240
 Amendment "A" and Response dated May 4, 2006
 Reply to Office Action mailed February 7, 2006



and pharmaceutically acceptable salts thereof, wherein:

EWG is an electron-withdrawing group selected from the group consisting of CHO, COR, COOH, COOR, NO₂, CN, SOR, SO₂R, and SO₂OR;

Z is selected from the group consisting of chlorine, bromine, and iodine;

R is an alkyl or aryl group selected from the group consisting of methyl, ethyl, propyl, i-propyl, butyl, s-butyl, t-butyl, phenyl, substituted phenyl, naphthyl, substituted naphthyl; and

n is an integer 3.

2. (Cancelled)

3. (Original) A pharmaceutical composition for treating microbial infections in a subject, comprising:

a therapeutically effective amount of an agent wherein the agent is selected from the compounds of claim 1, the agent being capable of altering an aspect of Type-I MetAP activity or structure in the subject so as to result in treatment of the bacterial infection; and

a pharmaceutically acceptable carrier.

4. (Original) A pharmaceutical composition for treating bacterial infections in a subject, comprising:

a therapeutically effective amount of an agent wherein the agent is selected from the compounds of claim 1, the agent being capable of altering an aspect of Type-I MetAP activity or structure in the subject so as to result in treatment of the bacterial infection; and

Application No. 10/786,240
Amendment "A" and Response dated May 4, 2006
Reply to Office Action mailed February 7, 2006


a pharmaceutically acceptable carrier.

5. (Currently Amended) A ~~compound~~ composition as recited in claim 4, wherein the subject is a human.


6. (Currently Amended) A ~~compound~~ composition as recited in claim 4, wherein the agent does not completely inhibit the activity of Type-II MetAP in the subject but is bactericidal by inhibiting the activity of Type-I MetAP in the subject.

7. (Withdrawn) A method of providing a dosage of an antibacterial compound to a subject in need thereof, the method comprising administering to the subject an effective amount of a compound as recited in claim 1.

8. (Currently Amended) A compound comprising a formula selected from the group consisting of:




Application No. 10/786,240
 Amendment "A" and Response dated May 4, 2006
 Reply to Office Action mailed February 7, 2006



and pharmaceutically acceptable salts thereof, wherein:

X is chlorine, bromine, or iodine;

Y is selected from the group consisting of: COCZ, C(EWG)Z, SOCZ, SO₂CZ,



and pharmaceutically acceptable salts thereof, wherein:

EWG is an electron withdrawing group selected from the group consisting of CHO, COR, COOH, COOR, NO₂, CN, SOR, SO₂R, and SO₂OR;

R is an alkyl or aryl group selected from the group consisting of methyl, ethyl, propyl, i-propyl, butyl, s-butyl, t-butyl, phenyl, substituted phenyl, naphthyl, and substituted naphthyl; and

n is an integer of 5 or less.

9. (Original) A compound as recited in claim 8, wherein n is selected from 4 and 5.

Application No. 10/786,240
Amendment "A" and Response dated May 4, 2006
Reply to Office Action mailed February 7, 2006

10. (Original) A pharmaceutical composition for treating bacterial infections in a subject, comprising:

a therapeutically effective amount of an agent wherein the agent is selected from the compounds of claim 8, the agent being capable of altering an aspect of Type-I MetAP activity or structure in the subject so as to result in treatment of the bacterial infection; and

a pharmaceutically acceptable carrier.


11. (Currently Amended) A ~~compound~~ composition as recited in claim 10, wherein the subject is a human.

12. (Currently Amended) A ~~compound~~ composition as recited in claim 10, wherein the agent does not completely inhibit the activity of Type-II MetAP in the subject but is bactericidal by inhibiting the activity of Type-I MetAP.

13. (Withdrawn) A method of providing a dosage of an antibacterial compound to a subject in need thereof, the method comprising administering to the subject an effective amount of a compound as recited in claim 8.

Application No. 10/786,240
Amendment "A" and Response dated May 4, 2006
Reply to Office Action mailed February 7, 2006

14. (Currently Amended) A compound comprising a formula selected from the group consisting of:



and pharmaceutically acceptable salts thereof, wherein:

EWG is an electron withdrawing group selected from the group consisting of CHO, COR, COOH, COOR, NO₂, CN, SOR, SO₂R, and SO₂OR;

Application No. 10/786,240
Amendment "A" and Response dated May 4, 2006
Reply to Office Action mailed February 7, 2006

R is an alkyl or aryl group selected from the group consisting of methyl, ethyl, propyl, i-propyl, butyl, s-butyl, t-butyl, phenyl, substituted phenyl, naphthyl, substituted naphthyl; and

n is an integer of 5 or less.

15. (Original) A compound as recited in claim 14, wherein n is selected from 4 and 5.
16. (Original) A pharmaceutical composition for treating bacterial infections in a subject, comprising:
- a therapeutically effective amount of an agent wherein the agent is selected from the compounds of claim 14, the agent being capable of altering an aspect of Type-I MetAP activity or structure in the subject so as to result in treatment of the bacterial infection; and
 - a pharmaceutically acceptable carrier.
17. (Currently Amended) A ~~compound~~ composition as recited in claim 16, wherein the subject is a human.
18. (Currently Amended) A ~~compound~~ composition as recited in claim 16, wherein the agent does not completely inhibit the activity of Type-II MetAP in the subject but is bactericidal by inhibiting the activity of Type-I MetAP.
19. (Withdrawn) A method of providing a dosage of an antibacterial compound to a subject in need thereof, the method comprising administering to the subject an effective amount of a compound as recited in claim 14.
20. (Withdrawn) A method of providing an antibacterial dosage to a subject in need thereof which comprises:
- administering to a subject an effective amount of a compound that is selectively configured to inhibit Type-I MetAP, the compound comprising the formula:

Application No. 10/786,240
Amendment "A" and Response dated May 4, 2006
Reply to Office Action mailed February 7, 2006

A-B-C

wherein:


A is a functional group selected to covalently bond with a recognition site on Type-I MetAP;

C is an electrophilic functional group selected to inhibit a catalytic site on Type-I MetAP; and

B is a series of groups selected to separate A and C such that each of A and C effectively bind to the respective recognition and active sites on Type-I MetAP;

and pharmaceutically acceptable salts thereof.

21. (Withdrawn) A method as recited in claim 20, wherein A comprises




wherein X is selected from the group consisting of CH₂SH, CH₂OH, NHOH, PO₃H₂, pyrazoles, imidazoles, oxazoles, isoxazoles, thiazoles, isothiazoles, triazoles, oxadiazoles and thiadiazoles.

22. (Withdrawn) A method as recited in claim 20, wherein B comprises a four or five carbon chain.

23. (Withdrawn) A method as recited in claim 20, wherein C is selected from the group consisting of: COCZ, C(EWG)Z, SO₂CZ,

Application No. 10/786,240
 Amendment "A" and Response dated May 4, 2006
 Reply to Office Action mailed February 7, 2006



wherein:

EWG is an electron withdrawing group selected from the group consisting of CHO, COR, COOH, COOR, NO₂, CN, SOR, SO₂R, and SO₂OR;

Z is selected from the group consisting of chlorine, bromine, and iodine; and

R is an alkyl or aryl group selected from the group consisting of methyl, ethyl, propyl, isopropyl, butyl, s-butyl, t-butyl, phenyl, substituted phenyl, naphthyl, substituted naphthyl.

24. (Withdrawn) A method as recited in claim 20, wherein the antibacterial dosage further comprises a pharmaceutically acceptable carrier.

25. (Withdrawn) A method as recited in claim 20, wherein the compound does not completely inhibit the activity of Type-II MetAP in the subject but is bactericidal by inhibiting the activity of Type-I MetAP in the subject.